VivoSeq
Oncology

Advanced Solid Tumor

38

Pipeline Programs

63

Active Trials

67

Companies Involved

Advanced Solid Tumor is a moderately active landscape with 38 programs across 67 companies. The most active players are BeOne Medicines, EMD Serono Research & Development Institute, Inc., Teva. 1 program is in Phase 3.

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

37/100

Mech. Concentration

25/100

Completion Rate

74/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

94%

Small molecule

33 of 35 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody26%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 93% of 40 pipeline programs.

Trial Status

158

clinical trials

Recruiting44 · 28%
Unknown status42 · 27%
Completed39 · 25%
Not yet recruiting11 · 7%
Terminated10 · 6%
Active, not recruiting7 · 4%
Other5 · 3%

Trial Activity

158 trials

Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)